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ABSTRACT 
Objectives: The objective of the present study is to formulate the Colon targeted delivery containing Naproxen for chronopharmaceutical drug 
delivery system (ChrDDS) for treatment of rheumatoid arthritis, which are influenced by circadian rhythm. Chronopharmaceutical drug delivery 
system is capable of delivering drug when and where drug required most. Naproxen would remain in the GIT Fluid, intestinal fluid and it will 
liberate only in colonic fluid and gives better absorption. 
Methods: The matrix core tablets of Naproxen were prepared by direct compression method by using Crosspovidone as superdisintegrant. From 
those optimesd batch core tablet is further going for coating. Coating was carried out by using natural gums like Xanthan gum, Guar gum, Chitosan 
and Pectin alone and in combination. 
Results: From the experimental work Crosspovidone shows good drug release. Coating done by combination of Xanthan Gum and Chitosan shows 
better drug release (98.24%) in sustained release manner than other natural gums like Guar gum and pectin. 
Conclusion: From the results obtained, it was concluded that the programmable Chronopharmaceutical drug release has been achieved from 
Crosspovidone containing core tablet compressed coated by combination of Xanthan gum and Chitosan over a 10 hrs period, consistent with the 
demands of chronotherapeutic drug delivery for rheumatoid arthritis. 
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INTRODUCTION 
The oral route is considered to be most convenient for 
administration of drugs to patients1. Nearly 50% of drug delivery 
systems available in the market are oral drug delivery systems and 
these systems have more advantages due to patient acceptance and 
ease of administration. In recent years, colon-specific drug delivery 
system (CDDS) have been developing as one of the site specific drug 
delivery system.Along with many application in local and systemic 
delivery of drugs the CDDS would also be advantageous when a 
delay in absorption is desirable from a therapeutic point of view as 
for the treatment of diseases that have a peak symptom in the early 
morning and that exhibit circadian rhythm, such as angina, asthma 
and rheumatoid arthritis2
Chronotherapy coordinates drug delivery with human biological 
rhythms and holds huge promise in areas of pain management and 
treatment of asthma, heart disease and cancer. The coordination of 
medical treatment and drug delivery with such biological clocks and 
rhythms is termed chronotherapy. The goal of chronotherapeutics is 




Theoretically, optimum therapy is more likely to result when the 
right amount of drug is delivered to the correct target organ at the 
most appropriate time. In contrast, many side effects can be 
minimized if a drug is not given when it is needed[4-6]. Naproxen 
itself is rapidly and completely absorbed from the GI tract with an 
in-vivo bioavailability of 95%. Although Naproxen is well absorbed, 
the sodium salt form is more rapidly absorbed resulting in higher 
peak plasma levels for a given dose[7-8]. Arthritis is a 
chronomodulated disease. The attacks of arthritis is usually occurs 
in the early morning (4 to 5 o’clock). In this research work, an 
attempted has been done to develop a dosage form which deliver the 
Naproxen at colon and get released in the early morning.  
.  
MATERIALS AND METHODS 
Naproxen was obtained as a gift sample from Devi’s laboratories 
limited, Hyderabad. All other ingredients were used of analytical 
grade. 
Methods 
The core tablets were prepared by direct compression technique. All 
materials were thoroughly mixed with mortar and pestle and passed 
through the mesh to ensure complete mixing. The powder weighting 
180 mg was taken and compressed into tablets using 8mm round, 
flat and plain punches on a single station tablet punching machine. 
Then the core tablets were coat compress coated method. For 
compression coating, 50% of granular material was first placed in 
the die cavity. Then, the core tablet ease carefully positioned at the 
center manually, which was then filled with the remaining 50% of 
granular material. The coating material was then compressed 
around the core tablet by using 12 mm round, flat, plain punches9
Drug-excipients interaction study [10,11] 
.  
The technique employed in this study is Fourier transform Infrared 
spectroscopy using FTIR (IR Affinity-1, Shimadzu, Japan). Fourier 
Transform Infrared spectroscopy is one of the most powerful 
analytical techniques which offer the possibility of identifying 
chemical interaction between drug and excipients. The diffusion 
reflectance spectroscopy technique was utilized in the mid-IR (400–
4000 cm-1) spectral region Powder mixture of drug and polymers in 
the ratio of 1:1 were prepared in KBr discs. The samples were placed 
in the light path and the spectra were obtained Infrared was 
performed in duplicate for each of the samples. 
Evaluation 
Hardness [12,13]  
Hardness indicates the ability of tablet to withstand mechanical 
shocks while handling. The hardness of the tablets was determined 
using Pfizer hardness tester. It was expressed in kg/cm2
Friability [14,15] 
. 
The friability of the tablets was determined using Roche friabilator. 
It is expressed in percentage (%). Approximately 6.5 gm (Wo) of 
deducted tablets were subjected to rotate at 25 rpm for 4 minutes in 
a rotating drum of 6 inches and are then reweighed (W) The 
friability was given by following formula.  
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% Loss= Initial wt. of – final wt. of tablets
Two wistar rats of body weight (150-200g) with no prior drug 
treatment were used for all the present ex vivo studies and 
maintained on normal diet and administered 1ml of 2% dispersion 
of pectin in water and this treatment was continue for 7 days in 
order to include the enzyme that specifically act on pectin or 
xanthan gum or guar gum, 30 minutes before starting the study, 
each rat was sacrificed and abdomen was opened. The caecum was 
traced, legated at both ends, dissected and immediately transferred 
in to phosphate buffered saline (PBS) pH 6.8, which was previously 
bubbled with CO
 ×100 
Initial wt. of tablet 
Weight variation test [16] 
Twenty tablets were weighed individually on weighing balance 
(Shimadzu, Japan), average weight was calculated and individual tablet 
weights were compared to the average weight The stablets met the USP 
test if no more than 2 tablets are outside the percentage limit and if no 
tablet differs by more than two times the percentage limit.  
In Vitro drug release studies in presence of rat caecal material 
[17, 18] (SIP/IAEC/08/2013-2014) 
2. The caecal bag was opened, the contents were 
weighed homogenized and then suspended in simulated colonic 
fluid of pH 7.4 to give desired concentration of 2% caecal content. 
The experiment was carried out with a continuous supply of CO2 in 
to the dissolution media. Drug release studies for first 5 hr were 
performed as described under section describing In vitro drug 
release studies in simulated gastro intestinal fluid. After 5 hrs 
release studies were carried out in simulated colonic fluid 
containing rat caecal material. Aliquots of samples were withdrawn 
periodically and replaced with fresh buffer bubbled with CO2
Drug content [19] 
.The 
samples were filtered through a whatman filter paper and drug 
content was determined spectrophotometrically. 
Ten tablets were weighed and average weight was calculated. All the 
10 tablets were crushed in a mortar. The powder equivalent to 10 
mg was accurately weighed, dissolved in 5 ml of Methanol & made 
upto 100 ml of 0.1 N HCl. The volumetric flask was then shaken for 
approximately 20 minutes. The solution was filtered and 1 ml of 
filtrate was diluted to 10 ml using 0.1 N HCl. Absorbance was 
measured at 264.5 nm using 0.1 N HCl as a blank. The amount of 
drug present in one tablet was calculated. 
Stability studies [20, 21] 
The optimized formulation was charged for the accelerated stability 
studies according to ICH guidelines (40 ± 2ºC and 75 ± 5% RH). The 
tablets were packed in high density polyethylene (HDPE) container 
and were stored in ICH certified stability chamber for 3 
months(zone III conditions as per ICH Q1guidelines) The samples 
were withdrawn at the end of 1 month for 3 months and evaluated 
for various parameters. 
 
Formulation Table 
Table 1: Composition of colon tablets 
Composition of Core tablets 
Ingredients  
(mg) 
F1 F2 F3 F4 F5 F6 F7 
Naproxen 150 150 150 150 150 150 150 
Crosspovidone  9 9 9 9 9 9 9 
MCC 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
PVP K30 9 9 9 9 9 9 9 
Mg. stearate 2.7 2.7 2.7 2.7 2.7 2.7 2.7 
Talc  1.8 1.8 1.8 1.8 1.8 1.8 1.8 
Composition of Compress coated tablets 
Xanthan gum 150 - - - 75 75 75 
Guar gum - 150 - - 75 - - 
Chitosan - - 150 - - 75 - 
Pectin - - - 150 - - 75 
Starch  1.8 1.8 1.8 1.8 1.8 1.8 1.8 
MCC 109.5 109.5 109.5 109.5 109.5 109.5 109.5 
 PVP K30  15 15 15 15 15 15 15 
Mg. stearate  4.5 4.5 4.5 4.5 4.5 4.5 4.5 
Talc  3 3 3 3 3 3 3 
Total (mg) 480 480 480 480 480 480 480 
  
RESULTS AND DISCUSSION  
Drug-excipient interaction study  
 
Fig. 1: IR spectral analysis of Naproxen 
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Fig. 2: IR spectral analysis Naproxen + polymer mixture 
• No interaction was found between drug and polymer mixture means drug is compatible with the polymer mixture. 
 
Table 2: Evaluation of Compressed coated Tablets 












F1 6.2±0.32 0.84% 482.5±1.22 98.02±0.04 
F2 6.1±0.37 0.79% 481.2±1.74 98.44±0.01 
F3 6.4±0.39 0.78% 480.2±1.37 99.63±0.5 
F4 5.7±0.47 0.74% 478.5±1.75 98.08±0.07 
F5 6.4±0.39 0.96% 481.8±1.19 97.51±0.09 
F6 5.5±0.42 0.86% 483.5±1.25 98.09±0.07 
F7 6.1±0.37 0.91% 478.2±1.20 98.45±0.01 
 
Table 3: Stability study of optimized formulation (F6) 
Parameters Initially After 1 months After 2 months After 3 months 
Hardness(Kg/cm2) 5.5±0.42 (n=3) 5.4±0.58 5.4±0.74 5.4±0.91 
Friability (%) 0.86% 0.88% 0.89% 0.89% 
% In vitro drug release (10th 98.24  hrs) 98.11 97.88 97.34 
Drug content (%) 99.26±0.07 98.89±0.11 98.47±0.25 98.43±0.14 
 
 
Fig. 3: In-vitro drug Release study of Compressed coated colon 
tablets 
 
• Hardness of the formulations F1-F7 was found to be in the range 
of 5.5±0.42 to 6.4±0.43 and friability limit for all the formulations 
were below 1%. 
• Drug content of all the formulations was found to be in the range 
of 97.51±0.09 % to 99.63±1.5 %. 
• The in vitro drug release was found to be in the range of 65.19 to 
98.24 %. 
Stability Studies 
From the stability studies, it was observed that there were no 
significant changes in the physical evaluation parameters, drug 
content and In vitro release study of optimized F6 formulation, and 
therefore the formulation is stable. 
CONCLUSION 
Based on the result obtained, the F6 was selected as the optimum 
formulation for colon drug delivery system. Polymers used in this 
study are suitable for colon targeting. In-vitro drug release in 
phosphate buffer 7.4pH with rat ceacal material was 98.24%. 
Compressed coated tablet for colon was able to retard the drug in 
upper GIT which reduces adverse effect and further sustained 
release of the drug in the colon was achieved by coat with Xanthan 
gum and Chitosan in combination. This design can be used for colon 
targeted delivery of Naproxen for treatment of rheumatoid arthritis. 
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